[go: up one dir, main page]

ATE310014T1 - Hepatitis b-impfstoff - Google Patents

Hepatitis b-impfstoff

Info

Publication number
ATE310014T1
ATE310014T1 AT95907092T AT95907092T ATE310014T1 AT E310014 T1 ATE310014 T1 AT E310014T1 AT 95907092 T AT95907092 T AT 95907092T AT 95907092 T AT95907092 T AT 95907092T AT E310014 T1 ATE310014 T1 AT E310014T1
Authority
AT
Austria
Prior art keywords
pct
mhbsag
fragment
sec
vaccine
Prior art date
Application number
AT95907092T
Other languages
English (en)
Inventor
Peter Karayiannis
Howard Christopher Thomas
Original Assignee
Imperial College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imperial College filed Critical Imperial College
Application granted granted Critical
Publication of ATE310014T1 publication Critical patent/ATE310014T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00Reverse transcribing DNA viruses
    • C12N2730/00011Details
    • C12N2730/10011Hepadnaviridae
    • C12N2730/10111Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00Chemistry: molecular biology and microbiology
    • Y10S435/975Kit
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/806Antigenic peptides or proteins
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/81Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82Proteins from microorganisms
    • Y10S530/826Viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
AT95907092T 1994-02-02 1995-02-02 Hepatitis b-impfstoff ATE310014T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9401987A GB9401987D0 (en) 1994-02-02 1994-02-02 Modified nucleic acid
PCT/GB1995/000208 WO1995021189A1 (en) 1994-02-02 1995-02-02 Hepatitis b vaccine

Publications (1)

Publication Number Publication Date
ATE310014T1 true ATE310014T1 (de) 2005-12-15

Family

ID=10749735

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95907092T ATE310014T1 (de) 1994-02-02 1995-02-02 Hepatitis b-impfstoff

Country Status (16)

Country Link
US (1) US5856084A (de)
EP (1) EP0741745B1 (de)
JP (1) JP3812949B2 (de)
KR (1) KR100370341B1 (de)
CN (1) CN1057774C (de)
AT (1) ATE310014T1 (de)
AU (1) AU693154B2 (de)
CA (1) CA2182375A1 (de)
DE (1) DE69534617T2 (de)
ES (1) ES2258767T3 (de)
GB (1) GB9401987D0 (de)
MX (1) MX9603182A (de)
NZ (1) NZ278937A (de)
PL (1) PL315784A1 (de)
SG (1) SG49631A1 (de)
WO (1) WO1995021189A1 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595739A (en) * 1993-05-07 1997-01-21 Abbott Laboratories Hepatitis B virus mutants, reagents and methods for detection
GB9608626D0 (en) * 1996-04-25 1996-07-03 Univ College Of London Hepatitis b monoclonal antibodies
EP0919568A1 (de) 1997-12-01 1999-06-02 Sorin Diagnostics S.r.l. Fluchtmutanten des Oberflächenantigens des Hepatitis B Virus
UA73475C2 (en) 1998-06-19 2005-08-15 Government Of Republic Singapo Hepatitis b virus strain, induced by vaccine, nucleic acid isolated molecule coding mutant main surface antiigen of hepatitis b virus, vector and vector system for the preparation of polypeptide, a method for the preparation of polypeptide (variants), purified polypeptide (variants), oligonucleotide, a method for the preparation of antibodies (variants), antibody (variants), a method for the determination of chemical compound for treating the infection of hepatitis b strain infection, a composition, a method for the preparation of composition, a method of organism liquids screening for hepatitis b virus, a method of antibody use, vaccine against hepatitis
US6787142B2 (en) 2001-04-30 2004-09-07 Government Of Republic Of Singapore Mutant human hepatitis B viral strain and uses thereof
NZ508890A (en) * 1998-06-19 2004-04-30 Government Of The Republic Of Singapore A mutant human hepatitis B viral strain and used thereof
FR2803599B1 (fr) * 2000-01-06 2004-11-19 Inst Nat Sante Rech Med Nouveau virus mute de l'hepatite b, ses constituants nucleiques et proteiques et leurs applications
KR100368756B1 (ko) * 2000-02-01 2003-01-24 주식회사 엘지생명과학 비형 간염 표면 항원에 대한 항체 진단 시약의 제조방법,이를 이용하여 수득되는 비형 간염 항원에 대한 항체 진단시약 및 비형 간염 바이러스 항체 진단 시약
ES2370169T3 (es) 2002-06-14 2011-12-13 Gen-Probe Incorporated Composiciones y métodos para detectar el virus de la hepatitis b.
CN100355777C (zh) * 2003-02-10 2007-12-19 文洪模 乙型肝炎病毒pre-S突变蛋白及其制备方法与应用
JP4898434B2 (ja) * 2003-06-20 2012-03-14 シーメンス・ヘルスケア・ダイアグノスティックス・プロダクツ・ゲーエムベーハー B型肝炎ウィルスの新規の表面タンパク質(HBsAg)変異体
WO2006033368A1 (ja) * 2004-09-22 2006-03-30 Advanced Life Science Institute, Inc. B型肝炎ウイルスs抗原の検出法
JP4948783B2 (ja) * 2005-05-18 2012-06-06 シスメックス株式会社 抗HBsモノクローナル抗体
CN100520409C (zh) * 2005-09-06 2009-07-29 珠海丽珠试剂有限公司 新型乙型肝炎病毒表面抗原确认试剂盒
NZ616512A (en) 2011-04-21 2015-05-29 Isis Pharmaceuticals Inc Modulation of hepatitis b virus (hbv) expression
CN102292870B (zh) * 2011-06-16 2013-09-11 华为技术有限公司 相控阵天线对准方法和装置以及相控阵天线
KR102558839B1 (ko) 2015-03-25 2023-07-25 아이쥐엠 바이오사이언스 인코포레이티드 다가 b형 간염 바이러스 항원 결합 분자 및 그의 용도
MX2022003658A (es) 2019-09-30 2022-04-25 Gilead Sciences Inc Vacunas contra el virus de la hepatitis b (vhb) y metodos para tratar el vhb.

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9007024D0 (en) * 1990-03-29 1990-05-30 Imperial College Novel vaccine
CA2067003A1 (en) * 1991-04-29 1992-10-30 Peter J. Kniskern Hbsag escape mutant vaccine
US5595739A (en) * 1993-05-07 1997-01-21 Abbott Laboratories Hepatitis B virus mutants, reagents and methods for detection

Also Published As

Publication number Publication date
EP0741745B1 (de) 2005-11-16
GB9401987D0 (en) 1994-03-30
WO1995021189A1 (en) 1995-08-10
KR100370341B1 (ko) 2003-04-11
US5856084A (en) 1999-01-05
MX9603182A (es) 1997-05-31
SG49631A1 (en) 1998-06-15
AU693154B2 (en) 1998-06-25
EP0741745A1 (de) 1996-11-13
JP3812949B2 (ja) 2006-08-23
NZ278937A (en) 1998-06-26
CA2182375A1 (en) 1995-08-10
CN1143373A (zh) 1997-02-19
ES2258767T3 (es) 2006-09-01
JPH09508284A (ja) 1997-08-26
DE69534617D1 (en) 2005-12-22
CN1057774C (zh) 2000-10-25
PL315784A1 (en) 1996-12-09
AU1542695A (en) 1995-08-21
DE69534617T2 (de) 2006-07-20

Similar Documents

Publication Publication Date Title
NZ237611A (en) Variant hepatitis b surface antigen
ATE310014T1 (de) Hepatitis b-impfstoff
BR9306820A (pt) Conjugado de um antígeno fracamente imunogênico e um veículo peptideo sintetico vacina processos para melhorar a imunogenicidade de uma molecula de antigeno fracamente imunogenico e para imunizar um hospedeiro mamífero
PT101052A (pt) Proteinas hibridas uteis na preparacao de vacinas
MA24638A1 (fr) Vaccin
HK1032511A1 (en) Proteins encoded by polynucleic cids of porcine reproductive and respiratory syndrome virus (prrsv)
AU668094B2 (en) Seroreactive regions on HPV 16 proteins E1 and E2
NZ295056A (en) Hepatitis virus e strain, recombinant proteins thereof, use in diagnostic methods and vaccines
EP1326895B8 (de) Monoklonale antikörper gegen hepatitis b virus
DE69126486D1 (de) Induzierung eines schutzes gegen virale infektionen
CA2286399A1 (en) Recombinant proteins of a pakistani strain of hepatitis e and their use in diagnostic methods and vaccines
WO2002051865A3 (fr) Antigenes proteiques inducteurs d'anticorps neutralisant le virus vih
NZ532271A (en) Peptide mimics of conserved gonococcal epitopes and methods and compositions using them
DE59209899D1 (de) Rekombinante Proteine mit der Immunreaktivität des Hepatitis B Virus e Antigens (HBeAg), Verfahren zu ihrer Herstellung und ihre Verwendung in Immunoassays und Impfstoffen
NZ334582A (en) Polyprotein construct of a papillomavirus
SE9304291L (sv) Diagnostiskt antigen och förfarande för in vitro diagnostisering av en aktiv infektion förorsakad av hepatit C virus

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties